- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2016–2027 · research · R01
Axonal transport and chemotherapy induced peripheral neuropathy
Rosalind A. Segal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2030 · research · R35
Integrating targeted therapy and immunotherapy to break through cancer
Jean Zhao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · research · R50
Stapled Peptides for Protein Interaction Research and Therapeutic Targeting in Human Cancer
Gregory Howard Bird · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
Program Integration
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Proteomics
Steven A Carr · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · program · P01
Administrative Core
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
Biostatistics Core
Donna S. Neuberg · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
Discovery of clinically distinct CLL subgroups by integrative mapping of large-scale CLL genetic, expression and clinical data
Gad A Getz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
Biospecimens and Primagraft Development
Jennifer R Brown · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · program · P01
Structural Approaches to HIV-1 Immunogen Design and BNAb Analysis
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Pathology
Ruben D Carrasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Administrative Core
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
CLL clonal evolution and the development of therapy-driven resistance
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Biostatistics
Jeremy M. Simon · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Defining the determinants of response and resistance to therapy for Richter's Syndrome
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · program · P01
Biomaterials and Nanovaccines
Darrell J Irvine · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Biostatistics
Donna S. Neuberg · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Administrative Core
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Functional identification of drug response and resistance in Richter's Syndrome
Anthony G Letai · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Functional identification of drug response and resistance in Richter's Syndrome
Anthony G Letai · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Biospecimens
Matthew S Davids · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Pathology
Ruben D Carrasco · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Proteomics
Steven A Carr · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
Functional identification of CLL drug response and resistance
Anthony G Letai · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · program · P01
Ex vivo Analysis of Autoreactive T Cells from Patients with Multiple Sclerosis
Vijay K. Kuchroo · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Defining the determinants of response and resistance to therapy for Richter's Syndrome
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Generating an atlas of Richter's Syndrome: from molecular understanding to outcome prediction, detection and monitoring
Gad A Getz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
Administrative Core
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · program · P01
Generating an atlas of Richter's Syndrome: from molecular understanding to outcome prediction, detection and monitoring
Gad A Getz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2021 · research · R35
How do genome alterations cause human lung cancer?
Matthew L. Meyerson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2022 · research · R35
Targeting intratumor heterogeneity in breast cancer
Kornelia Polyak · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · career development · K08
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemia
Birgit Knoechel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Therapeutic targeting of Fibroblast Growth Factor Receptors in Squamous Cancers
Adam Joel Bass · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Genetic evolution of glioblastomas during radiation and temozolomide therapy
Rameen Beroukhim · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
Targeting the cytokine circuitry of KRAS-driven lung cancer
David A Barbie · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · grant · BCRP
Therapeutic Targeting of Nonmalignant "Accessory" Cells in Bone Metastases of Hormone-Resistant ER-Positive Breast Cancer
Aedin Culhane · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2015–2020 · research · R01
Precision Medicine For Pediatric Low-Grade Gliomas
Daphne A. Haas-Kogan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2025 · research · R01
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M
Michael J Eck · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · research · R01
The function of cyclin C in tumorigenesis
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2015–2020 · cooperative agreement · U24
Quantitative Radiomics System Decoding the Tumor Phenotype
Hugo Aerts · Dana-Farber Cancer Institute · funded by National Institutes of Health
